Stay updated with breaking news from Cold Genesys. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CG Oncology’s main asset is cretostimogene, an oncolytic virus in late-stage development as a treatment for advanced bladder cancer. The IPO filing follow the report of interim efficacy data showing a 75% complete response rate.
CG Oncology Inc. has spent more than a decade trying to find solutions to bladder cancer. Investors believe the researcher is getting closer.
Latest research report, titled “Global Gene Therapies for Cancer Treatment Market Insights 2021 and Forecast 2026, This includes overview and deep stu